In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Audited Standalone & Consolidated Financial results for the Quarter & Year ended ....

Qualified audit opinionRevenue growth above 20%Profit growth above 25%Negative operating cash flowEBITDA margin compressionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.3%Reaction day

₹14.00

prior close

₹13.46

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-5.4% vs market

Pharmaceuticals peers, median of 147sector-0.1%-5.2% vs sector

On the reaction day the stock moved 5.4 pts less than Nifty Microcap 250 and 5.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.3

10m

-1.9

15m

-1.4

30m

-2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.3+0.1-5.4-0.1-5.2

Next day

-6.4-0.2-6.2-0.2-6.3

-6.6+0.3-7.0-0.2-6.4

-5.6+0.9-6.5+0.0-5.6

-6.0+0.8-6.8+0.0-6.0

-6.0+2.2-8.2+0.6-6.6

-6.4+3.4-9.7+1.4-7.8

15d

-9.7-0.8-8.9-2.9-6.8

-10.7+2.9-13.6+0.3-11.0

-10.7+0.8-11.6-0.4-10.4

-15.9+0.0-15.9-3.2-12.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gennex Laboratories reported audited standalone revenue from operations of ₹9,457.79 Lacs for FY25, up ~41.6% YoY from ₹6,679.87 Lacs, while standalone net profit rose ~19% to ₹1,403.68 Lacs (vs ₹1,179.79 Lacs). Consolidated revenue surged ~59% to ₹13,790.30 Lacs and consolidated net profit grew ~37.6% to ₹1,812.49 Lacs. However, Q4 standalone net profit fell sharply to ₹150.20 Lacs from ₹392.86 Lacs, dragged by higher material, employee and finance costs. The statutory auditor (R Pugalia & Company) issued a qualified opinion on both standalone and consolidated results, citing pending confirmations/reconciliations of various asset and liability balances with unascertainable impact — flagged as a repetitive qualification. The Board also appointed Mr. Sandeep Kumar Daga as Non-Executive Non-Independent Director and noted the resignation of Dr. S CH Dharma Rao.

Likely market impact

Strong full-year revenue and profit growth is encouraging, but the recurring qualified audit opinion, sharply weaker Q4 standalone profits, margin compression, and negative operating cash flows point to unresolved accounting reconciliations and rising costs that shareholders should monitor closely.